[ad_1]
This “2021 Biosimilars Global Market Report: COVID-19 Growth and Changes to 2030” Report has been added to ResearchAndMarkets.com supply.
The global biosimilar hormone market is expected to grow from USD 1.94 billion in 2020 to USD 2.19 billion in 2021, with a compound annual growth rate (CAGR) of 12.9%. The market is expected to reach 5.35 billion U.S. dollars by 2025, with a compound annual growth rate of 25%.
The main players in the biosimilar hormone market are Teva Pharmaceuticals, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals and GC Pharma.
The biosimilar hormone market includes the sale of biosimilar hormones by entities engaged in the production of biosimilar hormones. These hormones are used when the patient’s hormones are down or out of balance. Only include goods and services that are traded between entities or sold to end consumers.
Strict regulations on the approval of hormone biosimilars have restricted the growth of the biosimilar hormone market. The approval of biosimilars meets the same drug quality, efficacy and safety standards applicable to all biologics approved by the European Union. There should be similarities…
The full story can be found on Benzinga.com
[ad_2]
Source link
